Serum and CSF cytokines and matrix metalloproteinases in spinal tuberculosis

Inflammation Research

Volumn 64, Issue 2, 2015, Pages 97-106

  Patil, Tushar ^a   Garg, Ravindra Kumar ^a   Jain, Amita ^a   Goel, Madhu Mati ^a   Malhotra, Hardeep Singh ^a   Verma, Rajesh ^a   Singh, Gyan Prakash ^a   Sharma, Praveen Kumar ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Mycobacterium tuberculosis; Pott s spine; Spinal cord; Spinal tuberculosis; Tuberculosis

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; ETHAMBUTOL; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; ISONIAZID; MATRIX METALLOPROTEINASE; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BARTHEL INDEX; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TUBERCULOUS SPONDYLITIS; BLOOD; CEREBROSPINAL FLUID; YOUNG ADULT;

ADULT; CYTOKINES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; TUBERCULOSIS, SPINAL; YOUNG ADULT;

EID: 84925513853     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-014-0786-5     Document Type: Article

References (39)

1. World Health Organization. Global tuberculosis report 2012. Geneva, Switzerland: World Health Organization; 2012. Available at http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf.
2. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120:316–53.
3. Garg RK, Somvanshi DS. Spinal tuberculosis: a review. J Spinal Cord Med. 2011;34:440–54.
4. Dlugovitzky D, Torres-Morales A, Rateni L, Farroni MA, Largacha C, Molteni O, et al. Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement. FEMS Immunol Med Microbiol. 1997;18:203–7.
5. Handzel ZT, Barak V, Altman Y, Bibi H, Lidgi M, Iancovici-Kidon M, et al. Increased Th1 and Th2 type cytokine production in patients with active tuberculosis. Isr Med Assoc J. 2007;9:479–83.
6. Salgame P. MMPs in tuberculosis: granuloma creators and tumor destroyers. J Clin Invest. 2011;121:1686–8.
7. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. (WHO/HTM/TUBERCULOSIS/2009.420) World Health Organization; 2010. Available at http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf.
8. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 1988;10:61–3.
9. Govender S, Annamalai K, Kumar KP, Govender UG. Spinal tuberculosis in HIV positive and negative patients: immunological response and clinical outcome. Int Orthop. 2000;24:163–6.
10. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41(Suppl 3):S194–8.
11. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602–10.
12. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60:1884–94.
13. Raja A. Immunology of tuberculosis. Indian J Med Res. 2004;120:213–32.
14. Mootoo A, Stylianou E, Arias MA, Reljic R. TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets. 2009;8:53–62.
15. Oleĭnik VV, Potapenko EI, Iakunova OA. TNF-alpha in prognosis of a recovery of the spinal marrow function in patients with spinal tuberculosis. Probl Tuberk Bolezn Legk. 2003;5:26–8.
16. Nemeth J, Winkler HM, Boeck L, Adegnika AA, Clement E, Mve TM, et al. Specific cytokine patterns of pulmonary tuberculosis in Central Africa. Clin Immunol. 2011;138:50–9.
17. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, Van Der Poll T. Serum concentrations of cytokines in patients with active tuberculosis and after treatment. Clin Exp Immunol. 1999;115:110–3.
18. Cowan J, Pandey S, Filion LG, Angel JB, Kumar A, Cameron DW. Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and pro-inflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol. 2012;167:317–29.
19. Giacomini E, Iona E, Ferroni L, Miettinen M, Fattorini L, Orefici G, et al. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol. 2001;166:7033–41.
20. Mansour AM, Frenck RW Jr, Darville T, Nakhla IA, Wierzba TF, Sultan Y, et al. Relationship between intracranial granulomas and cerebrospinal fluid levels of gamma interferon and interleukin-10 in patients with tuberculous meningitis. Clin Diagn Lab Immunol. 2005;12:363–5.
21. Motsinger-Reif AA, Antas PR, Oki NO, Levy S, Holland SM, Sterling TR. Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet. 2010;11:37.
22. Zhang Y, Doerfler M, Lee TC, Guillemin B, Rom WN. Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components. J Clin Invest. 1993;91:2076–83.
23. Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber KD, et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1β production in human macrophages. J Immunol. 2011;187:2540–7.
24. Kleinnijenhuis J, Joosten LA, van de Veerdonk FL, Savage N, van Crevel R, Kullberg BJ, et al. Transcriptional and inflammasome-mediated pathways for the induction of IL-1beta production by Mycobacterium tuberculosis. Eur J Immunol. 2009;39:1914–22.
25. Mayer-Barber KD, Barber DL, Shenderov K, White SD, Wilson MS, Cheever A, et al. Caspase-1 independent IL-1beta production is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signalling in vivo. J Immunol. 2010;184:3326–30.
26. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun. 1997;65:4843–9.
27. Narendran G, Andrade BB, Porter BO, Chandrasekhar C, Venkatesan P, Menon PA, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One. 2013;8:e63541.
28. Vani J, Shaila MS, Rao MK, Krishnaswamy UM, Kaveri SV, Bayry J. B lymphocytes from patients with tuberculosis exhibit hampered antigen-specific responses with concomitant overexpression of interleukin-8. J Infect Dis. 2009;200:481–2.
29. Lee JH, Chang JH. Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis. Korean J Intern Med. 2003;18:138–45.
30. Ma X, Reich RA, Wright JA, Tooker HR, Teeter LD, Musser JM, et al. Association between interleukin-8 gene alleles and human susceptibility to tuberculosis disease. J Infect Dis. 2003;188:349–55.
31. Hur YG, Gorak-Stolinska P, Ben-Smith A, Lalor MK, Chaguluka S, Dacombe R, et al. Combination of cytokine responses indicative of latent TB and active TB in Malawian adults. PLoS One. 2013;8:e79742.
32. da Silva MV, Figueiredo AA, Machado JR, Castellano LC, Alexandre PB, Oliveira RF, et al. T cell activation and pro-inflammatory cytokine production in clinically cured tuberculosis are time-dependent and accompanied by upregulation of IL-10. PLoS One. 2013;8:e65492.
33. Lago PM, Boéchat N, Migueis DP, Almeida AS, Lazzarini LC, Saldanha MM, et al. Interleukin-10 and interferon-gamma patterns during tuberculosis treatment: possible association with recurrence. Int J Tuberc Lung Dis. 2012;16:656–9.
34. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008;19:34–41.
35. Green JA, Dholakia S, Janczar K, Ong CW, Moores R, Fry J, et al. Mycobacterium tuberculosis-infected human monocytes down-regulate microglial MMP-2 secretion in CNS tuberculosis via TNFα, NFκB, p38 and caspase 8 dependent pathways. J Neuroinflammation. 2011;8:46.
36. Vatansever S, Gelisgen R, Uzun H, Yurt S, Kosar F. Potential role of matrix metalloproteinase-2,-9 and tumor inhibitors of metalloproteinase-1,-2 in exudative pleural effusions. Clin Invest Med. 2009;32:E293–300.
37. Lee KY, Kim EH, Yang WS, Ryu H, Cho SN, Lee BI, et al. Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis. J Neurol Sci. 2004;220:73–8.
38. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis. 2002;6:713–9.
39. Xiong C, Zhan X, Xiao Z. Transcript levels of major MMPs and ADAMTS-4 in relation to the clinicopathological profile of patients with tuberculous intervertebral discs and healthy controls. Clin Biochem. 2013;46:603–11.